in the scientific literature. Shipped to the Centers for Disease Control and Prevention for testing on a live virus, the prototype proved to be 1,000 times more effective than the original compound in inhibiting 3CLpro.
However, Johnson, said, the prototype drug blocked several, but not all, of the enzyme's pockets. "The goal is to create compounds that will block all possible binding sites in the proteases to put them out of business."
"A compound that blocks all these sites, rather than just a few, and that conforms tightly to the pockets, is ultimately a better drug for human consumption because it can be prescribed in smaller doses."
Johnson emphasized that all the work being done at UIC involves isolated proteases, not live viruses. "The proteases are no more dangerous than the enzymes in your laundry detergent," he said.
Testing of the protease inhibitors on live viruses will be done at the U.S. Centers for Disease Control and Prevention.
SARS was first reported in Guangdong Province, China in November 2002 and spread rapidly to other Asian countries, North America and Europe. By July of the following year, more than 8,000 cases were reported in 26 countries on five continents, resulting in 774 deaths and enormous economic damage.
Source:University of Illinois at Chicago
Page: 1 2 3 Related biology news :1
. First real-time view of developing neurons reveals surprises, say Stanford researchers2
. Emergence of cancer as major cause of childhood death in developing countries is not being adequately addressed3
. Elusive salamanders have role in developing new sampling models4
. Free access to a digital library for developing countries5
. Neurons find their place in the developing nervous system with the help of a sticky molecule6
. DOE publishes research roadmap for developing cleaner fuels7
. Replacing insulin is top-ranked breakthrough foreseen for health in developing world8
. New test helps identify hepatitis C patients at high risk of developing cirrhosis9
. Cheaper, better disease treatments expected from faster approach to developing antibodies